Vortioxetine, a new multimodal agent in development for the treatment of major depression, shows effects on cognitive function in several preclinical animal models
· New preclinical data for vortioxetine presented at the American Psychiatric Association demonstrate differences from other antidepressants (SSRI/SNRI) in studies of cognitive function · In animals the data show the effect of vortioxetine in models assessing a variety of cognitive functions, including attention, memory and executive function · These preclinical data provide additional evidence for the mode of action of vortioxetine and the critical role of activity at specific serotonin receptors to explain the differences observed from SSRI and SNRI antidepressants Valby, Denmark,